MANTLE CELL LYMPHOMA

This trial tests whether giving anti-inflammatory drugs directly into the spinal fluid at the first sign of a brain-related side effect can stop it from becoming severe. The study enrolls adults with non-Hodgkin lymphoma who are receiving CD19 CAR T cell therapy, a treatment that…

This phase 1 trial tests an experimental therapy called 20-19 Tan BB06z CAR-T for people with certain blood cancers (like lymphoma or leukemia) that have come back or not responded to treatment. The therapy involves taking a patient's own immune T cells, genetically modifying the…

This clinical trial is testing whether adding an experimental drug called HDM2005 to a standard treatment (rituximab and lenalidomide) can help people with mantle cell lymphoma whose cancer has returned or not responded to previous therapies. The study involves about 40 adults an…

This early-phase trial tests a new treatment for people with B-cell non-Hodgkin lymphoma that has not responded to at least two prior therapies. Participants receive donor immune cells (NK cells) along with two antibody drugs (rituximab and tafasitamab) and a support drug (IL-2) …

This pilot study tests whether a connected blood pressure monitor, supervised daily by a healthcare assistant, helps patients with blood cancers like CLL or lymphoma stick to home monitoring. The goal is to catch and manage high blood pressure early, a common side effect of BTK i…

This early-phase study tests a new type of immune cell therapy (CAR T cells) that targets two proteins on cancer cells at once. It is for adults with B-cell non-Hodgkin lymphoma whose cancer has not responded to or has returned after other treatments. The main goal is to find a s…

This early-stage study tests a new treatment called RN1701 for people with B-cell lymphoma that has come back or not responded to other treatments. RN1701 is a type of immune cell therapy made from donor cells, designed to target two markers on cancer cells. The study will enroll…

This early study is testing a new treatment called RN1701 for people with B-cell lymphoma that has come back or not responded to standard treatments. RN1701 is a type of immunotherapy made from donor cells (allogeneic CAR-T) that targets two proteins on cancer cells. The main goa…

This trial tests a new treatment called SHB-02-CD19, which uses a patient's own immune cells engineered to attack cancer cells that have a protein called CD19. It is for children and adults with B-cell cancers (like leukemia or lymphoma) that have come back or not responded to at…

This early-phase study tests a new treatment called QH103 for adults with B-cell lymphoma that has come back or not responded to standard therapy. QH103 uses specially engineered immune cells (CAR-γδT cells) from healthy donors to target and kill cancer cells. The main goals are …

This early-phase study tests a new treatment called RN1701 for people with B-cell lymphoma that has come back or not responded to standard therapy. RN1701 uses specially engineered immune cells from a donor to target and kill cancer cells. The main goals are to check safety and s…

This early study tests a new treatment for people with B-cell blood cancers that have come back or not responded to standard therapy. The treatment uses donor immune cells (CAR-T cells) designed to find and attack cancer cells. The main goal is to check if it's safe, with a small…

This phase 2 study tests pirtobrutinib, a daily oral drug, as a first treatment for elderly patients (70+) with mantle cell lymphoma who are considered unfit or frail. The goal is to see if the drug can control the cancer and delay progression. 56 participants will take the drug …

This study tests a new treatment for mantle cell lymphoma, a rare blood cancer. It combines chemotherapy with targeted drugs to see if it can keep the cancer from coming back. The study involves 45 people who have not been treated before, and uses scans and blood tests to guide t…

This early-stage trial will test a new immune cell therapy called CT1194D CAR-T in 20 adults with relapsed or refractory B-cell cancers (lymphoma or leukemia). The main goals are to check safety, find the right dose, and see how long the cells last in the body. Researchers will a…

This study investigates how often atrial fibrillation (AF), a type of irregular heartbeat, occurs in people with certain blood cancers who are starting a targeted cancer drug called a Bruton's tyrosine kinase inhibitor (BTKI). Researchers will follow 500 participants—400 starting…

This study collects blood and bone marrow samples from 80 people with B-cell non-Hodgkin lymphoma to explore why some cancers resist chemotherapy. Researchers will analyze the tumor and its environment, and develop lab models to test new treatments. The goal is to uncover resista…